IN SITU ANTIGEN-GENERATING CANCER VACCINE

The invention provides compositions and methods for utilizing scaffolds in cancer vaccines. 1. A biopsy-free method for producing a processed tumor antigen in situ comprising administering to a subject diagnosed with a cancer a porous 3-dimensional scaffold , said scaffold comprising a chemoattractant of cancer cells , maintaining said scaffold in situ for a time period sufficient to accumulate a circulating cancer cell to yield a cancer cell-containing scaffold , and contacting said cell-containing scaffold with a cytotoxic or cytolytic element to produce a processed tumor antigen.2. The method of claim 1 , wherein said cytotoxic element comprises application of external heat claim 1 , ultrasound claim 1 , laser radiation claim 1 , or gamma radiation to said cell-containing scaffold.3. (canceled)4. The method of claim 1 , wherein said scaffold further comprises a hyperthermia-inducing composition.510-. (Canceled)11. A tumor antigen-processing device comprising a porous polymer claim 1 , a chemoattractant for cancer cells claim 1 , and a cytotoxicity-inducing composition.12. The device of claim 11 , wherein said cytotoxicity-inducing composition comprises a hyperthermia-inducing particle.13. The device of claim 11 , wherein said cytotoxicity-inducing composition comprises a gold nanoparticle or a gold nanorod.14. The device of claim 11 , wherein said device further comprises an immune cell recruitment composition.15. (canceled)16. The device of claim 14 , wherein said chemoattractant claim 14 , cytotoxicity-inducing composition claim 14 , and immune cell recruitment composition are interspersed throughout said porous polymer.17. The device of claim 14 , wherein said porous polymer comprises a first zone comprising said chemoattractant and said cytotoxicity-inducing composition and a second zone comprising said immune cell recruitment composition.18. (canceled)19. A method of increasing plasmacytoid dendritic cell activation in a subject claim 11 , comprising ...

Mesoporous silica compositions for modulating immune responses

A composition comprising mesoporous silica rods comprising an immune cell recruitment compound and an immune cell activation compound, and optionally comprising an antigen such as a tumor lysate. The composition is used to elicit an immune response to a vaccine antigen.

In situ antigen-generating cancer vaccine

The invention provides compositions and methods for utilizing scaffolds in cancer vaccines.

Nanoparticle Targeting to Ischemia for Imaging and Therapy

The invention provides compositions and methods that provide a solution to the difficulties in diagnosing ischemia, e.g., identifying specific affected anatomical areas, and treating ischemic tissue so as to minimize damage and promote healing of damaged tissue in a subject such as a human or other animal. 1. A pharmaceutical composition comprising a non-liposomal nanoparticle comprising an angiogenesis-promoting factor linked thereto.2. The composition of claim 1 , wherein said factor is a growth factor or cytokine.3. The composition of claim 1 , wherein said factor is selected from the group consisting of vascular endothelial growth factor (VEGF) claim 1 , basic fibroblast growth factor (bFGF) claim 1 , platelet derived growth factor (PDGF) claim 1 , placental growth factor (PLGF) claim 1 , Angiopoietin claim 1 , stromal-derived factor (SDF) claim 1 , granulocyte-macrophage colony stimulating factor (GM-CSF) claim 1 , and granulocyte colony stimulating factor (G-CSF).4. The composition of claim 1 , wherein said factor is VEGF.5. The composition of claim 1 , wherein said nanoparticle further comprises a directed targeting composition that binds to or associates with ICAM-1 claim 1 , P-selectin claim 1 , E-selectin claim 1 , or αβintegrin.6. The composition of claim 5 , wherein said directed targeting composition is an antibody or fragment thereof.7. A method for preferentially promoting angiogenesis at an ischemic anatomical site compared to a non-ischemic site claim 1 , comprising administering to a subject identified as suffering from or suspected of suffering from ischemic and administering to said subject the composition of claim 1 , wherein said nanoparticle preferentially localizes to said ischemic anatomical site compared to said non-ischemic site.8. A method for promoting angiogenesis at a target anatomical site in a subject claim 1 , comprising locally administering to said target site an EPR-inducing agent and subsequently administering to said subject ...

Mesoporous Silica Compositions for Modulating Immune Responses

A composition comprising mesoporous silica rods comprising an immune cell recruitment compound and an immune cell activation compound, and optionally comprising an antigen such as a tumor lysate. The composition is used to elicit an immune response to a vaccine antigen. 1. A composition comprising mesoporous silica rods comprising an immune cell recruitment compound and an immune cell activation compound.2. The composition of claim 1 , wherein said rods comprise pores of between 2-50 nm in diameter.3. The composition of claim 1 , wherein said rods comprise pores of between 5-25 nm in diameter.4. The composition of claim 1 , wherein said rods comprise pores of between 5-10 nm in diameter.5. The composition of claim 1 , wherein said rods comprise pores of approximately 8 nm in diameter.6. The composition of claim 1 , wherein said rods comprise a length of 5 μm to 500 μm.7. The composition of claim 1 , wherein said rods a length of 5 μm to 25 μm.8. The composition of claim 1 , wherein said rods comprise a length of 80 μm to 120 μm.9. The composition of claim 1 , wherein said recruitment compound comprises granulocyte macrophage-colony stimulating factor (GM-CSF) claim 1 , chemokine (C-C motif) ligand 21 (CCL-21) claim 1 , chemokine (C-C motif) ligand 19 (CCl-19) claim 1 , or a FMS-like tyrosine kinase 3 (Flt-3) ligand.10. The composition of claim 1 , wherein said recruitment compound comprises GM-CSF.11. The composition of claim 1 , wherein said composition further comprises an antigen.12. The composition of claim 11 , wherein said antigen comprises a tumor antigen.13. The composition of claim 11 , wherein said antigen comprises a tumor cell lysate.14. A method of inducing a systemic antigen-specific immune response to a vaccine antigen claim 1 , comprising administering to a subject the composition of .15. Use of a composition comprising mesoporous silica rods comprising an immune cell recruitment compound claim 1 , an immune cell activation compound claim 1 , and a ...

Cell-Friendly Inverse Opal Hydrogels for Cell Encapsulation, Drug and Protein Delivery, and Functional Nanoparticle Encapsulation

The invention provides polymer scaffolds for cell-based tissue engineering. 1. An inverse opal hydrogel scaffold device comprising a polymer matrix and a sacrificial porogen , wherein said porogen comprises an ionically-crosslinked polymer , a thermosensitive polymer , a thermoresponsive polymer , a pH-sensitive polymer , or a photocleavable polymer.2. The inverse opal hydrogel of claim 1 , wherein said polymer matrix further comprises an isolated eukaryotic cell.3. The inverse opal hydrogel of claim 1 , wherein said polymer matrix is crosslinked and wherein scaffold device further comprises an isolated cell encapsulated in said crosslinked polymer matrix.4. The inverse opal hydrogel of claim 1 , wherein said polymer matrix comprises a synthetic polymer.5. The inverse opal hydrogel of claim 1 , wherein said polymer matrix comprises covalent crosslinking6. The inverse opal hydrogel of claim 1 , wherein said polymer matrix comprises a poly(lactide-coglycolide) (PLGA) claim 1 , poly(acrylic acid) claim 1 , polyethylene glycol (PEG) claim 1 , poly (vinyl alcohol) claim 1 , or polyphosphazene.7. The inverse opal hydrogel of claim 1 , wherein said sacrificial porogen comprises alginate claim 1 , collagen claim 1 , gelatin claim 1 , fibrin claim 1 , agarose claim 1 , hyaluronic acid claim 1 , or chitosan.8. The inverse opal hydrogel of claim 1 , wherein said ionically crosslinked polymer comprises alginate.9. The inverse opal hydrogel of claim 1 , wherein said ionically crosslinked polymer is removed by adding a metal-chelating agent selected from the group consisting of citric acid claim 1 , ethylenediamine claim 1 , ethylenediaminetetraacetic acid (EDTA) claim 1 , diethylenetriaminepentaacetic acid (DTPA) claim 1 , and N claim 1 ,N-bis(carboxymethyl)glycine (NTA).10. The inverse opal hydrogel of claim 1 , wherein said thermosensitive polymer comprises agarose claim 1 , gelatin claim 1 , or collagen.11. The inverse opal hydrogel of claim 1 , wherein said thermoresponsive ...

In Situ Antigen-Generating Cancer Vaccine

The invention provides compositions and methods for utilizing scaffolds in cancer vaccines. 1. A biopsy-free method for producing a processed tumor antigen in situ comprising administering to a subject diagnosed with a cancer a porous 3-dimensional scaffold , said scaffold comprising a chemoattractant of cancer cells , maintaining said scaffold in situ for a time period sufficient to accumulate a circulating cancer cell to yield a cancer cell-containing scaffold , and contacting said cell-containing scaffold with a cytotoxic or cytolytic element to produce a processed tumor antigen.2. The method of claim 1 , wherein said cytotoxic element comprises application of external heat claim 1 , ultrasound claim 1 , laser radiation claim 1 , or gamma radiation to said cell-containing scaffold.3. The method of claim 2 , wherein said laser radiation comprises ultraviolet or near infrared laser radiation.4. The method of claim 1 , wherein said scaffold further comprises a hyperthermia-inducing composition.5. The method of claim 4 , wherein said hyperthermia-inducing composition comprises a magnetic nanoparticle or a near infrared (NIR) absorbing nanoparticle.6. The method of claim 5 , wherein said nanoparticle is magnetic claim 5 , and wherein said method further comprises contacting said magnetic nanoparticle with an alternately magnetic field to induce local hyperthermia in situ claim 5 , thereby disrupting said cancer cell and producing a processed tumor antigen.7. The method of claim 5 , wherein said NIR nanoparticle is selected from the group consisting of a gold nanorod claim 5 , gold nanoshell claim 5 , gold nanocage claim 5 , noble metal nanoparticle claim 5 , carbon nanotube claim 5 , carbon nanoparticle claim 5 , and graphite nanoparticle claim 5 , and wherein said method further comprises contacting said NIR nanoparticle with NIR radiation to induce local hyperthermia in situ claim 5 , thereby disrupting said cancer cell and producing a processed tumor antigen.8. The ...

Multi-layered cell constructs and methods of use and production using enzymatically degradable natural polymers

The present disclosure relates generally to the fields of tissue engineering and regenerative medicine. More particularly, the present disclosure generally relates to systems, methods, compositions and kits to rapidly fabricate functionalized three-dimensional tissues from multiple stacks of cell sheets using enzyme-digestible hydrogel substrates as supports for the cell sheets. Methods to generate the multi-layered cell constructs comprise contacting a cell-sheet on one digestible substrate with another cell-sheet on a different digestible substrate, enzymatically digesting with a first enzyme to remove the first substrate and subsequently adding repeating the steps to add another cell-sheet on same digestible substrate to form a multi-layered cell construct as disclosed herein. Additional aspects relate to using the multi-layered cell constructs for therapeutic use, research and in screening assays.

AZIDE-BASED COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE AZIDE-BASED COMPOUND, AND METHOD OF MANUFACTURING THE ORGANIC LIGHT-EMITTING DEVICE

Provided are an azide-based compound, an organic light-emitting device including the azide-based compound, and a method of manufacturing the organic light-emitting device. 2. The organic light-emitting device of claim 1 , whereinthe first electrode is an anode,the second electrode is a cathode,the organic layer comprises at least one of the azide-based compound represented by Formula 1,the organic layer further comprises a hole transport region between the first electrode and the emission layer and an electron transport region between the emission layer and the second electrode,the hole transport region comprises a hole injection layer, a hole transport layer, an emission auxiliary layer, an electron blocking layer, or any combination thereof, andthe electron transport region comprises a hole blocking layer, an electron transport layer, an electron injection layer, or any combination thereof.3. The organic light-emitting device of claim 2 , whereinthe hole transport region comprises the at least one of the azide-based compound.4. The organic light-emitting device of claim 3 , whereinthe hole transport region further comprises a polymer having a molecular weight of about 5,000 g/mol or greater.5. The organic light-emitting device of claim 1 , whereinthe emission layer comprises a host material and a dopant material, andthe dopant material comprises a phosphorescent dopant or a fluorescent dopant.7. The azide-based compound of claim 6 , wherein{'sub': 1', '2', '3, 'each of L, L, and Lis independently a single bond.'}8. The azide-based compound of claim 6 , wherein{'sub': 11', '12, 'claim-text': a single bond, a methylene group, an ethylene group, a propylene group, a butylene group, and a pentylene group; and', {'sub': 1', '10, 'a methylene group, an ethylene group, a propylene group, a butylene group, and a pentylene group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a ...

Composition, organic layer prepared therefrom, and apparatus including the organic layer

A composition for forming an organic layer in an organic light-emitting device includes a high-molecular-weight compound represented by Formula 1, having a molecular weight of about 50,000 or more; a non-arylamine-based low-molecular-weight compound represented by Formula 2, having a molecular weight of about 10,000 or less; and a solvent: wherein in Formula 2, Y is a substituted or unsubstituted C 3 -C 60 carbocyclic group that does not include a moiety represented by When the composition is deposited and dried to form the organic layer, the organic layer is solvent resistant.

CERIA NANOCOMPOSITE COMPRISING CERIA NANOPARTICLE FOR TREATING SUBARACHNOID HEMORRHAGE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION

Provided are a ceria nanocomposite including a ceria nanoparticle for treating subarachnoid hemorrhage, a method of preparing the same, and a pharmaceutical composition including the ceria nanocomposite. The ceria nanocomposite for treating subarachnoid hemorrhage disclosed herein includes a ceria nanoparticle and a surface modified layer disposed on a surface of the ceria nanoparticle, wherein the surface modified layer includes a polyethylene glycol residue. 1. A ceria nanocomposite comprising a ceria nanoparticle and a surface modified layer disposed on a surface of the ceria nanoparticle , wherein the surface modified layer comprises a polyethylene glycol (PEG) residue.2. The ceria nanocomposite of claim 1 , wherein the surface modified layer comprises an outer layer comprising the PEG residue and an inner layer whose one end is combined with the ceria nanoparticle and the other end is combined with the PEG residue.3. The ceria nanocomposite of claim 2 , wherein the inner layer comprises a residue of a polyfunctional organic compound comprising a first terminal group capable of binding to the ceria nanoparticle and a second terminal group capable of binding to a PEG derivative which is an origin of the polyethylene glycol residue.4. The ceria nanocomposite of claim 3 , wherein the polyfunctional organic compound comprises an aliphatic amino carboxylic acid.5. The ceria nanocomposite of claim 3 , wherein the PEG derivative comprises methoxy PEG succinimidyl glutarate claim 3 , methoxy PEG succinimidyl barate claim 3 , methoxy PEG succinimidyl carbonate claim 3 , methoxy PEG succinimidyl succinate claim 3 , methoxy PEG succinimidyl propionate claim 3 , or a combination thereof.6. The ceria nanocomposite of claim 1 , wherein the ceria nanocomposite has an average particle diameter of 5 nm to 100 nm.7. A method of preparing a ceria nanocomposite for eating subarachnoid hemorrhage claim 1 , the method comprising:preparing a mixed solution containing a cerium ...

CROSS-LINKABLE ARYLAMINE-BASED COMPOUND, POLYMER OBTAINED THEREFROM, LIGHT-EMITTING DEVICE INCLUDING THE POLYMER, AND ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE

Provided is a cross-linkable arylamine-based compound represented by Formula 1a or 1b, a polymer obtained therefrom, a light-emitting device including the polymer, and an electronic apparatus including the light-emitting device. The light-emitting device includes a first electrode; a second electrode facing the first electrode; and an intermediate layer between the first electrode and the second electrode and comprising an emission layer, wherein the intermediate layer includes at least one of the arylamine-based polymer formed by cross-linking a cross-linkable arylamine-based compound represented by Formula 1a or 1b. 2. The light-emitting device of claim 1 , wherein:the emission layer comprises at least one selected from an organic compound and a semiconductor compound,wherein the organic compound comprises a host and a dopant, andthe semiconductor compound comprises a quantum dot.3. The light-emitting device of claim 1 , wherein:the first electrode is an anode,the second electrode is a cathode, andthe intermediate layer further comprises i) a hole transport region between the first electrode and the emission layer and comprising a hole injection layer, a hole transport layer, a buffer layer, an electron blocking layer, or any combination thereof and ii) an electron transport region between the emission layer and the second electrode and comprising a hole blocking layer, an electron transport layer, an electron injection layer, or any combination thereof.4. The light-emitting device of claim 3 , wherein:the hole transport region comprises at least one of the arylamine-based polymer.5. The light-emitting device of claim 3 , wherein:the hole transport region comprises a hole injection layer and a hole transport layer, andthe hole transport layer comprises at least one of the arylamine-based polymer.6. The light-emitting device of claim 2 , wherein:the hole transport region is formed by using one selected from vacuum deposition, spin coating, casting, Langmuir- ...

Organic light-emitting device and method of manufacturing the same

Provided are an organic light-emitting device and a method of manufacturing the same. The organic light-emitting device includes: a first electrode; a second electrode facing the first electrode; and an organic layer between the first electrode and the second electrode and including an emission layer. The organic layer includes a hole transport region between the first electrode and the emission layer. The hole transport region also includes a first compound and a second compound, or includes the first compound and a third compound.

Arylamine-based compound including thermally decomposable groups and organic light-emitting device including the same

Provided are an organic light-emitting device including an arylamine-based compound including a thermally decomposable group, and an arylamine-based compound including a thermally decomposable group. The organic light-emitting device includes: a first electrode; a second electrode facing a first electrode; and an organic layer between the first electrode and the second electrode and including an emission layer, the organic layer including an arylamine-based compound in which the thermally decomposable group has been thermally decomposed and removed from the arylamine-based compound including the thermally decomposable group.

CERIA NANOCOMPOSITE FOR BIOMEDICAL TREATMENT AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

Disclosed are a ceria nanocomposite for biomedical treatment, including a ceria nanoparticle; and a pharmaceutical composition. The disclosed ceria nanocomposite for biomedical treatment includes a ceria nanoparticle and a surface modification layer arranged on the surface of the ceria nanoparticle, wherein the surface modification layer includes a polyethylene glycol residue, and in the ceria nanoparticle, the content of Ceis greater than the content of Ce. 1. A ceria nanocomposite for biomedical treatment , the ceria nanocomposite comprising a ceria nanoparticle having a surface , and a surface modification layer disposed on the surface of the ceria nanoparticle ,wherein the surface modification layer comprises a polyethylene glycol residue, and{'sup': 3+', '4+, 'in the ceria nanoparticles, the content of Ce is greater than the content of Ce.'}2. The ceria nanocomposite for biomedical treatment of claim 1 , whereinthe surface modification layer comprises an outer layer including the polyethylene glycol residue and an inner layer of which one end is linked to the ceria nanoparticle and the other end is linked to the polyethylene glycol residue.3. The ceria nanocomposite for biomedical treatment of claim 1 , whereinthe inner layer comprises a residue of a multifunctional organic compound, and the multifunctional organic compound has a first terminal group capable of binding to the ceria nanoparticle and a second terminal group capable of binding to a polyethylene glycol derivative which is an origin of the polyethylene glycol residue.4. The ceria nanocomposite for biomedical treatment of claim 3 , whereinthe multifunctional organic compound comprises aliphatic aminocarboxylic acid.5. The ceria nanocomposite for biomedical treatment of claim 3 , whereinthe polyethylene glycol derivative comprises methoxy PEG succinimidyl glutarate, methoxy PEG succinimidyl valerate, methoxy PEG succinimidyl carbonate, methoxy PEG succinimidyl succinate, methoxy PEG succinimidyl ...

Nanoparticle targeting to ischemia for imaging and therapy

The invention provides compositions and methods that provide a solution to the difficulties in diagnosing ischemia, e.g., identifying specific affected anatomical areas, and treating ischemic tissue so as to minimize damage and promote healing of damaged tissue in a subject such as a human or other animal.

Ceria nanocomposite comprising ceria nanoparticle for treating subarachnoid hemorrhage, method for preparing same, and pharmaceutical composition

Provided are a ceria nanocomposite including a ceria nanoparticle for treating subarachnoid hemorrhage, a method of preparing the same, and a pharmaceutical composition including the ceria nanocomposite. The ceria nanocomposite for treating subarachnoid hemorrhage disclosed herein includes a ceria nanoparticle and a surface modified layer disposed on a surface of the ceria nanoparticle, wherein the surface modified layer includes a polyethylene glycol residue.

Nanoparticle targeting to ischemia for imaging and therapy

The invention provides compositions and methods that provide a solution to the difficulties in diagnosing ischemia, e.g., identifying specific affected anatomical areas, and treating ischemic tissue so as to minimize damage and promote healing of damaged tissue in a subject such as a human or other animal.

Mesoporous silica compositions for modulating immune responses

A composition comprising mesoporous silica rods comprising an immune cell recruitment compound and an immune cell activation compound, and optionally comprising an antigen such as a tumor lysate. The composition is used to elicit an immune response to a vaccine antigen.

Nanoparticle targeting to ischemia for imaging and therapy

The invention provides compositions and methods that provide a solution to the difficulties in diagnosing ischemia, e.g., identifying specific affected anatomical areas, and treating ischemic tissue so as to minimize damage and promote healing of damaged tissue in a subject such as a human or other animal.

In situ antigen-generating cancer vaccine

The invention provides compositions and methods for utilizing scaffolds in cancer vaccines.

In situ antigen-generating cancer vaccine

The invention provides compositions and methods for utilizing scaffolds in cancer vaccines.

In situ antigen-generating cancer vaccine

Electrosurgical systems and methods

An electrosurgical device includes a plurality of electrodes for forming a plurality of bipolar circuits usable for affecting a patient's tissue during a surgical operation. At least one of said electrodes is operable as an active electrode in one of said bipolar circuits and as a return electrode in another one of said bipolar circuits.

Nanoparticle targeting to ischemia for imaging and therapy

The invention provides compositions and methods that provide a solution to the difficulties in diagnosing ischemia, e.g., identifying specific affected anatomical areas, and treating ischemic tissue so as to minimize damage and promote healing of damaged tissue in a subject such as a human or other animal.

Ceria nanoparticles and ceria nanoparticles preparation method

A ceria nanoparticles preparation method is provided. The method includes preparing a mixed solution containing a cerium precursor and an imidazole derivative and preparing ceria nanoparticles by stirring the mixed solution.

Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation

Vaccine for treating multiple sclerosis

The present disclosure relates to a vaccine composition for treating multiple sclerosis. The vaccine composition of the present disclosure induces immune tolerance and suppresses autoimmune response itself, thus can be usefully applied to the treatment of multiple sclerosis.